This could be it....
Companies often pay these promoters to prime the pump prior to a big announcement. This email was posted in my box at 4:30 pm on Tues. 9/11/18:
Hello,
New Trade Alert: Nemaura Medical Inc. (NASDAQ: NMRD)
Today we would like to bring to your attention NMRD, which we first presented to you earlier this year.
As a reminder, NMRD is a “medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system.”
When we first alerted NMRD it rallied upwards of 13%.
Following our second alert NMRD rallied 17%.
Once again, NMRD could present you with a breakout opportunity.
Over the past few weeks NMRD has consolidated below its 20 and 50 day moving averages.
In the event that NMRD continues to hold above its low seen a few weeks ago, and breaks out above and stays above its 20 and 50 day moving averages, this could present increased upside potential.
Earlier this year NMRD traded as high as 6.80. If NMRD were to return to these levels that would present upside potential of over 200%.
NMRD could be one of the few companies that has yet to experience significant upside in its sector.
NMRD’s closest competitors in the glucose monitoring sector have been reaching new all-time highs in the past few days and weeks. One of them even rallied upwards of 242% since 2017.
What’s interesting is that NMRD could have a better product than its competitors...
The current leading products in the market are invasive, requiring a needle like sensor to be inserted under the skin.
NMRD’s “patent-protected technology” on the other hand is “non-invasive” using an “adhesive skin-patch connected to a rechargeable transmitter”.
This could potentially be a game changer, and not only for people with diabetes…
According to the company’s website, “BEAT™ technology will allow for remote continuous monitoring of chronic diseases and health conditions”, “allowing both users and healthcare professionals to closely monitor chronic diseases.”
In the past few months NMRD has announced a number of potentially positive developments that could have been overlooked by investors.
Here is a summary from NMRD of it’s “Recent Highlights and Accomplishments”:
“SugarBEAT® commenced clinical trials for FDA approval and reported positive interim data from home-use portion of study.”
“With its approved contract manufacturers, Nemaura commenced manufacturing scale-up in preparation for anticipated launch in the United Kingdom in the coming months.”
“Nemaura placed an initial order with UK contract manufacturer for 12,500 sugarBEAT® rechargeable transmitters, which will be supplemented with approximately 100,000 skin-patches per month.”
NMRD presents a potentially compelling trade opportunity, which could continue to attract increased interest from Wall Street as more investors become familiar with the company.
If you agree, don’t miss this opportunity.
Source: PR1, PR2, PR3, WHO, Scientist, Website, Chart
Happy Trading!
AwesomeStocks
--------------------------
DISCLAIMER
This report/release is a commercial advertisement and is for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list. The track record, gains, upside, and/or losses mentioned are all hypothetical and should not be considered as the basis for investment. While we do not charge for the SMS service, standard carrier message and data rates may apply.
